Status:
COMPLETED
East New Britain Province Monitoring & Evaluation
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Case Western Reserve University
Washington University School of Medicine
Conditions:
Lymphatic Filariasis Elimination by Mass Drug Administration
Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
Eligibility:
All Genders
5-80 years
Brief Summary
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a p...
Detailed Description
Although the current two-drug regimen has been successful in many places, it is clear that augmented treatment regimens, other alternative strategies, or both are needed to accelerate global eliminati...
Eligibility Criteria
Inclusion
- All individuals ages 5 years to 80 years living in selected villages will be eligible to enroll.
- Must live in the villages for at least 12 months
Exclusion
- Minors ages 4 and under will not be eligible to enroll.
- Lived in selected village for less than 12 months.
Key Trial Info
Start Date :
September 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
12930 Patients enrolled
Trial Details
Trial ID
NCT04124250
Start Date
September 17 2019
End Date
January 1 2024
Last Update
November 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
East New Britain Provincial Health Authority
Kokopo, East New Britain Province, Papua New Guinea